- AtomVie Global Radiopharma has entered a strategic partnership with Ionetix Corporation to secure clinical-grade Actinium-225 for radiopharmaceutical development and manufacturing.
- Under the agreement, Ionetix will supply cGMP-grade Ac-225 to support AtomVie’s clients as they advance alpha-based therapies through clinical development.
AtomVie Global Radiopharma has announced a strategic partnership with Ionetix Corporation to enhance access to clinical-grade Actinium-225 (Ac-225) for radiopharmaceutical programmes worldwide. AtomVie operates as a contract development and manufacturing organisation (CDMO) specialising in GMP manufacturing and clinical supply of radiopharmaceuticals.
Under the agreement, Ionetix will supply cGMP-grade Ac-225, an alpha-emitting radioisotope, for use in the development and manufacturing of AtomVie’s clients’ radiopharmaceutical products. The collaboration is intended to strengthen AtomVie’s service portfolio and support a growing pipeline of alpha-based therapies.
The announcement comes as AtomVie prepares to launch a new radiopharmaceutical manufacturing facility, with demand increasing for reliable supplies of therapeutic radioisotopes. The company said securing access to Ac-225 is an important factor in enabling clients to progress programmes from research into clinical development.
“Reliable access to high-quality alpha-emitting isotopes like Ac-225 is essential for the next generation of targeted radiopharmaceuticals.”
Bruno Paquin, Chief Executive Officer of AtomVie Global Radiopharma
AtomVie said the partnership allows it to integrate a dependable isotope supply into its CDMO and contract manufacturing services, supporting clinical supply requirements as interest in alpha-therapy development continues to grow globally.
